IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors

Journal of Neuro-Oncology

Volumn 105, Issue 2, 2011, Pages 345-357

  Mellai, Marta ^a   Piazzi, Angela ^b   Caldera, Valentina ^a   Monzeglio, Oriana ^a   Cassoni, Paola ^a   Valente, Guido ^b   Schiffer, Davide ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Brain tumors; IDH1 and IDH2 mutations; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; DNA SEQUENCE; GENE DELETION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC MARKER; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; MARKER GENE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; MUTATOR GENE; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; STOP CODON; TP53 GENE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEMALE; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; ISOCITRATE DEHYDROGENASE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 82955165744     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0596-3     Document Type: Article

References (48)

1. DW Parsons S Jones X Zhang, et al. 2008 An integrated genomic analysis of human glioblastoma multiforme Science 321 1807 1812 18772396 10.1126/science.1164382 1:CAS:528:DC%2BD1cXhtFCrtLrE
2. J Balss J Meyer W Mueller, et al. 2008 Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol 116 597 602 18985363 10.1007/s00401-008-0455-2 1:CAS:528:DC%2BD1cXhtlyhsbfN
3. H Yan DW Parsons G Jin, et al. 2009 IDH1 and IDH2 mutations in gliomas N Engl J Med 360 765 773 19228619 10.1056/NEJMoa0808710 1:CAS:528: DC%2BD1MXitFWru7o%3D
4. C Hartmann J Meyer J Balss, et al. 2009 Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Acta Neuropathol 118 469 474 19554337 10.1007/s00401-009-0561-9
5. S Nobusawa T Watanabe P Kleihues, et al. 2009 IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res 15 6002 6007 19755387 10.1158/1078-0432.CCR-09-0715 1:CAS:528:DC%2BD1MXhtF2ltbbL
6. K Ichimura DM Pearson S Kocialkowski, et al. 2009 IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas Neuro Oncol 11 341 347 19435942 10.1215/15228517-2009-025 1:CAS:528:DC%2BD1MXhtV2qur%2FF
7. T Watanabe S Nobusawa P Kleihues, et al. 2009 IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas Am J Pathol 174 1149 1153 19246647 10.2353/ajpath.2009.080958 1:CAS:528:DC%2BD1MXksVOksLY%3D
8. C Horbinski J Kofler LM Kelly, et al. 2009 Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues J Neuropathol Exp Neurol 68 1319 1325 19915484 10.1097/NEN.0b013e3181c391be 1:CAS:528:DC%2BD1MXhsVOhtLvE
9. Y Sonoda T Kumabe T Nakamura, et al. 2009 Analysis of IDH1 and IDH2 mutations in Japanese glioma patients Cancer Sci 100 1996 1998 19765000 10.1111/j.1349-7006.2009.01270.x 1:CAS:528:DC%2BD1MXht12qs7bP
10. Ikota H, Nobusawa S, Tanaka Y et al (2011) High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein. Brain Tumor Pathol 28:107-114
11. FE Bleeker S Lamba S Leenstra, et al. 2009 IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors Hum Mutat 30 7 11 19117336 10.1002/humu.20937 1:CAS:528: DC%2BD1MXivFygs7g%3D
12. Rakheja D, Mitui M, Boriack RL, Deberardinis RJ (2010) Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. Pediatr Blood Cancer 56:379-383
13. MR Kang MS Kim JE Oh, et al. 2009 Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers Int J Cancer 125 353 355 19378339 10.1002/ijc.24379 1:CAS:528:DC%2BD1MXms1amu70%3D
14. L Dang S Jin SM Su 2010 IDH mutations in glioma and acute myeloid leukemia Trends Mol Med 16 387 397 20692206 10.1016/j.molmed.2010.07.002 1:CAS:528:DC%2BC3cXhtFajs7zJ
15. Y Zou Y Zeng DF Zhang SH Zou YF Cheng YG Yao 2010 IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders Biochem Biophys Res Commun 402 378 383 20946881 10.1016/j.bbrc.2010.10.038 1:CAS:528:DC%2BC3cXhsValtrzK
16. M Holdhoff DW Parsons LA Diaz Jr 2009 Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer J Neurooncol 94 297 19350208 10.1007/s11060-009-9855-y
17. A von Deimling A Korshunov C Hartmann 2011 The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations Brain Pathol 21 74 87 10.1111/j.1750-3639.2010.00454.x
18. LA Gravendeel NK Kloosterhof LB Bralten, et al. 2010 Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma Hum Mutat 31 E1186 E1199 20077503 10.1002/humu.21201 1:CAS:528:DC%2BC3cXktVOns74%3D
19. T Watanabe A Vital S Nobusawa, et al. 2009 Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome Acta Neuropathol 117 653 656 19340432 10.1007/s00401-009-0528-x 1:CAS:528: DC%2BD1MXlvFOksb8%3D
20. K Narahara S Kimura K Kikkawa, et al. 1985 Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3 Hum Genet 71 37 40 3861566 10.1007/BF00295665 1:CAS:528:DyaL28XhsFGh (Pubitemid 16252285)
21. N Ramachandran RF Colman 1980 Chemical characterization of distinct subunits of pig heart DPN-specific isocitrate dehydrogenase J Biol Chem 255 8859 8864 7410398 1:CAS:528:DyaL3cXmtVSisr8%3D
22. DT Hartong M Dange TL McGee, et al. 2008 Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle Nat Genet 40 1230 1234 18806796 10.1038/ng.223 1:CAS:528:DC%2BD1cXhtFKht73K
23. L Dang DW White S Gross, et al. 2009 Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 739 744 19935646 10.1038/nature08617 1:CAS:528:DC%2BD1MXhsVGlurzE
24. MJ van den Bent HJ Dubbink Y Marie, et al. 2010 IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Clin Cancer Res 16 1597 1604 20160062 10.1158/1078-0432.CCR-09-2902
25. M Labussière A Idbaih XW Wang, et al. 2010 All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 Neurology 74 1886 1890 20427748 10.1212/WNL.0b013e3181e1cf3a
26. M Weller J Felsberg C Hartmann, et al. 2009 Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network J Clin Oncol 27 5743 5750 19805672 10.1200/JCO.2009.23.0805 1:CAS:528: DC%2BC3cXhtVWisbg%3D
27. M Sanson Y Marie S Paris, et al. 2009 Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J Clin Oncol 27 4150 4154 19636000 10.1200/JCO.2009.21.9832 1:CAS:528:DC%2BD1MXhtF2jtLrP
28. Toedt G, Barbus S, Wolter M et al (2010) Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer 128:1095-1103
29. HJ Dubbink W Taal R van Marion, et al. 2009 IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide Neurology 73 1792 1795 19933982 10.1212/WNL.0b013e3181c34ace 1:CAS:528:DC%2BD1MXhsVaks77K
30. C Houillier X Wang G Kaloshi, et al. 2010 IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas Neurology 75 1560 1566 20975057 10.1212/WNL.0b013e3181f96282 1:CAS:528:DC%2BC3cXhtlGmtrjK
31. D Capper H Zentgraf J Balss, et al. 2009 Monoclonal antibody specific for IDH1 R132H mutation Acta Neuropathol 118 599 601 19798509 10.1007/s00401-009- 0595-z 1:CAS:528:DC%2BD1MXhtlKitLrK
32. A Korshunov J Meyer D Capper, et al. 2009 Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma Acta Neuropathol 118 401 405 19543740 10.1007/s00401-009-0550-z 1:CAS:528: DC%2BD1MXptVGjt7c%3D
33. D Capper S Weissert J Balss, et al. 2010 Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors Brain Pathol 20 245 254 19903171 10.1111/j.1750-3639.2009.00352.x 1:CAS:528:DC%2BC3cXpvFOlsA%3D%3D
34. D Capper F Sahm C Hartmann, et al. 2010 Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes Am J Surg Pathol 34 1199 1204 20661018 10.1097/PAS.0b013e3181e7740d
35. S Camelo-Piragua M Jansen A Ganguly, et al. 2010 Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis Acta Neuropathol 119 509 511 20044756 10.1007/s00401-009-0632-y
36. YH Kim S Nobusawa M Mittelbronn, et al. 2010 Molecular classification of low-grade diffuse gliomas Am J Pathol 177 2708 2714 21075857 10.2353/ajpath.2010.100680
37. Louis DN, Ohgaki H, Wiestler OD et al (2007) WHO classification of tumors of the central nervous systems, 4th edn. International Agency for Research on Cancer (IARC), Lyon
38. M Mellai V Caldera L Annovazzi, et al. 2009 MGMT promoter hypermethylation in a series of 104 glioblastomas Cancer Genomics Proteomics 6 219 227 19656999 1:CAS:528:DC%2BD1MXhtVSjur7N
39. M Esteller SR Hamilton PC Burger, et al. 1999 Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59 793 797 10029064 1:CAS:528:DyaK1MXht1Sjurk%3D (Pubitemid 29086728)
40. M Weller H Berger C Hartmann, et al. 2007 Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13 6933 6937 18056167 10.1158/1078-0432.CCR-07-0573 1:CAS:528:DC%2BD2sXhtlyit7fL (Pubitemid 350276872)
41. W Xu H Yang Y Liu, et al. 2011 Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Cancer Cell 19 17 30 21251613 10.1016/j.ccr.2010.12.014 1:CAS:528: DC%2BC3MXpvValsQ%3D%3D
42. ME Figueroa O Abdel-Wahab C Lu, et al. 2010 Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 553 567 21130701 10.1016/j.ccr.2010.11.015 1:CAS:528:DC%2BC3cXhsFGhsbvJ
43. C Hartmann B Hentschel W Wick, et al. 2010 Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas Acta Neuropathol 120 707 718 21088844 10.1007/s00401-010-0781-z
44. P Metellus B Coulibaly C Colin, et al. 2010 Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis Acta Neuropathol 120 719 729 21080178 10.1007/s00401-010-0777- 8
45. P Cavalla A Dutto R Piva, et al. 1998 Cyclin D1 expression in gliomas Acta Neuropathol 95 131 135 9498046 10.1007/s004010050776 1:CAS:528: DyaK1cXjslyhsQ%3D%3D (Pubitemid 28076006)
46. I Bosone P Cavalla L Chiadò-Piat, et al. 2001 Cyclin D1 expression in normal oligodendroglia and microglia cells: its use in the differential diagnosis of oligodendrogliomas Neuropathology 21 155 161 11666011 10.1046/j.1440-1789.2001.00389.x 1:STN:280:DC%2BD3MrmsVWnsQ%3D%3D (Pubitemid 32947277)
47. S Diabira X Morandi 2008 Gliomagenesis and neural stem cells: key role of hypoxia and concept of tumor 'neo-niche' Med Hypotheses 70 96 104 17614215 10.1016/j.mehy.2007.04.024 1:CAS:528:DC%2BD2sXhsVSrsbfL (Pubitemid 350161161)
48. Schiffer D (2006) Brain tumor pathology: current diagnostic hotspots and pitfalls. Springer, The Netherlands